Mercer Global Advisors Inc. ADV Boosts Holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI)

Mercer Global Advisors Inc. ADV lifted its stake in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 9.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,376 shares of the medical instruments supplier’s stock after purchasing an additional 290 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in Merit Medical Systems were worth $290,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Opal Wealth Advisors LLC purchased a new stake in Merit Medical Systems during the 2nd quarter worth approximately $29,000. Parallel Advisors LLC raised its stake in Merit Medical Systems by 114.6% in the 4th quarter. Parallel Advisors LLC now owns 397 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 212 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in Merit Medical Systems in the 1st quarter valued at $44,000. Headlands Technologies LLC acquired a new stake in Merit Medical Systems during the 1st quarter worth $50,000. Finally, EntryPoint Capital LLC grew its holdings in shares of Merit Medical Systems by 2,666.7% during the first quarter. EntryPoint Capital LLC now owns 913 shares of the medical instruments supplier’s stock worth $69,000 after buying an additional 880 shares in the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on MMSI shares. Canaccord Genuity Group upped their price objective on shares of Merit Medical Systems from $102.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Wells Fargo & Company increased their price target on Merit Medical Systems from $85.00 to $103.00 and gave the company an “equal weight” rating in a report on Monday, September 16th. Baird R W upgraded Merit Medical Systems to a “strong-buy” rating in a research report on Friday, June 28th. Needham & Company LLC restated a “buy” rating and issued a $105.00 target price on shares of Merit Medical Systems in a report on Monday, September 16th. Finally, Barrington Research lifted their price target on Merit Medical Systems from $100.00 to $114.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $101.82.

Merit Medical Systems Price Performance

Merit Medical Systems stock opened at $97.68 on Monday. The company’s 50 day simple moving average is $92.98 and its 200-day simple moving average is $83.99. The company has a debt-to-equity ratio of 0.62, a quick ratio of 4.64 and a current ratio of 6.24. Merit Medical Systems, Inc. has a 1 year low of $62.58 and a 1 year high of $101.60. The company has a market capitalization of $5.68 billion, a price-to-earnings ratio of 56.14, a price-to-earnings-growth ratio of 2.52 and a beta of 0.87.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.04. Merit Medical Systems had a return on equity of 15.29% and a net margin of 9.02%. The company had revenue of $338.00 million for the quarter, compared to analysts’ expectations of $334.94 million. As a group, equities research analysts expect that Merit Medical Systems, Inc. will post 3.31 earnings per share for the current year.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.